Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Finally, we showed miR-106a overexpression upregulated the levels of Bcl-2 and ABCG2, and downregulated the expression of P53, Bax, and RUNX3. miR-106a promotes breast cancer cell proliferation and invasion through upregulation of Bcl-2, ABCG2, and P53, and downregulation of Bax and RUNX3.
|
30570350 |
2019 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the study identified the lncRNA AX747207, and its potential targeted gene RUNX3, may be related to chemoresistance in breast cancer.
|
29749447 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Analysis of whole genome expression profiles of breast cancer samples revealed significant co-relation between YAP-RUNX1/RUNX3 expression levels and survival outcomes of breast cancer patients.
|
29581836 |
2018 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Three breast cancer cell lines and 113 formalin-fixed, paraffin-embedded breast cancer tissue samples were analyzed for RUNX3 expression.
|
30133331 |
2018 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
DNA methylation is strongly associated with the repression of transcription through adding to the methyl group by DNA methyltransferases (DNMTs), and tumor suppressor genes such as CCND2 and RUNX3 have been investigated to undergo hypermethylation at promoter region in breast cancer.
|
29282690 |
2017 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
High RUNX3 mRNA expression was strongly associated with better relapse-free survival (RFS) in BC patients.
|
27825140 |
2017 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Six genes (ACADL, ADAMTSL1, CAV1, NPY, PTGS2, and RUNX3) showed significant differential methylation among the 4 breast cancer subtypes and also between the ER +/ER- tumors.
|
25636590 |
2015 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Further analysis also showed significantly increased OR of RUNX3 hypermethylation in estrogen receptor (ER)-positive than in ER-negative BC patients (OR =5.67, 95% CI =2.69-11.95, Z=4.57, P<0.00001).
|
25525332 |
2014 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent studies have suggested that RUNX3 acts as a tumor suppressor in stomach, colon and breast cancer.
|
23851507 |
2014 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
After adjustment for multiple comparisons, two SNPs were significantly associated with breast cancer risk: RUNX3 (rs906296 ORCG/GG = 1.15 95 % CI 1.04-1.26) and TGF-β1 (rs4803455 ORCA/AA = 0.89 95 % CI 0.81-0.98).
|
24036662 |
2013 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
However, the underlying mechanism for initiating RUNX3 inactivation in breast cancer remains elusive.
|
22580604 |
2013 |
Breast Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The classical tumor suppressor gene RUNX3 does not consist of such a mutation hot spot, but it too seems to inhibit BCa; it is often inactivated in human BCa tumors and its haploinsufficiency in mice leads to spontaneous BCa development.
|
23045283 |
2013 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review is intended to summarize these findings and discuss the tumor suppressor function of RUNX3 in breast cancer.
|
22275124 |
2012 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Recent studies have suggested that loss of RUNX3 expression is involved in stomach, colon and breast cancer.
|
22076387 |
2012 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Runt domain transcription factor, RUNX3, has been shown to be a tumor suppressor in a variety of cancers including gastric, colon and breast cancer.
|
21612813 |
2011 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, RUNX3 inactivation may not be a common association between CCLs and breast carcinomas.
|
20955380 |
2010 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
RUNX3 inactivation by frequent promoter hypermethylation and protein mislocalization constitute an early event in breast cancer progression.
|
18256927 |
2009 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The expression of RUNX3 mRNA and protein were negative in 3 breast cancer cell lines (T47D, MCF7 and SKBR3) as analyzed by RT-PCR and Western blotting.
|
18580070 |
2008 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
This finding also offers a mechanistic explanation as to why a tumor suppressor gene, such as RUNX3, can be heritably silenced by epigenetic mechanisms in breast cancer.
|
18339859 |
2008 |
Breast Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We show that RUNX3 is present at reduced CNs in proportion to the rest of the tumor genome and that RUNX3 CN reductions can also be observed in a breast cancer series from a different center.
|
17171680 |
2007 |
Breast Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Sixty-seven percent of breast cancer cell lines showed downregulated RUNX3 expression, but the RUNX3 gene was not expressed in two normal breast cell lines.
|
17923751 |
2007 |
Breast Carcinoma
|
0.100 |
PosttranslationalModification
|
disease |
BEFREE |
Fifty percent of the breast cancer cell lines (n = 19) showed hypermethylation at the promoter region and displayed significantly lower levels of RUNX3 mRNA expression (P < 0.0001) and protein (P < 0.001).
|
16818622 |
2006 |